The Baby Business and Public Policy
By Marcy Darnovsky,
Science Progress
| 05. 05. 2009
Regulation Can Ensure Well-being and Protect Reproductive Rights
The recent media storm over the in vitro fertilization-induced birth of octuplets has receded into the tabloids and entertainment pages. A second fertility industry scandal that emerged several weeks later-the announcement by a Los Angeles fertility clinic that it would soon offer a program to select embryos not just for sex but also for hair, eye and skin color-has also veered out of the headlines. But the outcry surrounding these events has revealed mounting disquiet about the multi-billion dollar baby business.
The fertility industry's professional societies offer a potential avenue for self-regulation of the field, but their existing recommendations are too often ignored. Other countries regulate assisted reproduction to protect the well-being of all participants, including the children whom it helps create and the families and society into which they are born. Drawing lessons from their successes could help temper the commercial pressures in the U.S. assisted reproduction sector, without in any way diminishing reproductive rights.
The importance of addressing these issues is readily evident. The octuplets story left a mark even on the English language. Google now reports one...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...